Logo

CP-223473 updated on 31-05-21

Referencer:

1. Spravato® produktresumé.

2. Molero P, Ramos-Quiroga JA, Martin-Santos R, et al. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs. 2018; 32(5): 411-420.

8. Popova V, Daly E, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression:A randomized double-blind

   active controlled study. Am J Psychiatry 2019; 176(6): 428-438.

9. Daly E, Trivedi M, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial. JAMA

   Psychiatry. 2019 Jun 5. doi: 10.1001/jamapsychiatry.2019.1189. [Epub ahead of print] https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2735111

11. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Preference and Adherence. 2012; 6: 369-388.

12. Taylor D, Barnes TRE, Young AH. The Maudsley Guidelines in Psychiatry. 13th Edition. Chapter 3, Wiley Blackwell, 2018.

13. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice Guideline for the treatment patients with major depressive disorder. Third edition. Part American Psychiatric Association, 2010.

14. Cleare A, Pariante CM, Young AH, et al. Members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for    Psychopharmacology guidelines. Journal of Psychopharmacology. 2015; 29(5): 459-525.

16. Rush AJ1, Trivedi MH, Wisniewski et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905‒1917.

23. Duman RS, Aghajanian GK, Sanacora G et al. Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med 2016; 22(3): 238–249.

41. Mattingly GW, Anderson RH. Intranasal esketamine. Current Psychiatry. 2019; 18(5): 31-38.

47. Penner J et al. Front Hum Neurosci: Medial Prefrontal and Anterior Insular Connectivity in Early Schizophrenia and Major Depressive Disorder: A Resting Functional MRI Evaluation of Large-Scale Brain Network Models. 2016; 10:132

48. Murrough JW et al. Nat Rev Drug Discov. Targeting glutamate signaling in depression: progress and prospects 2017;16(7):472-486


EM-51337 updated on 13.01.21

Referencer:

1: Spravato® produktresumé.

2: Mattingly GW, Anderson RH. Intranasal esketamine. Current Psychiatry. 2019; 18(5): 31-38

3: Popova V, Daly E, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression:A randomized double-blind active controlled study. Am J Psychiatry 2019; 176(6): 428-438.

4: Daly E, Trivedi M, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial. JAMA Psychiatry. 2019 Jun 5. doi: 10.1001/jamapsychiatry.2019.1189. [Epub ahead of print] https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2735111

Spravato® – Introduktion (Jesper Riise - Medical Advisor)

EM-38962

Do you have a medical question?

Do you have a product related question?

EM-51347 - January 2021